Tag Archives: Jack Meehan

Syneos Health Inc (SYNH) Gets a Hold Rating from Barclays

In a report released yesterday, Jack Meehan from Barclays maintained a Hold rating on Syneos Health Inc (SYNH – Research Report), with a price target of $48. The company’s shares closed yesterday at $48.48. According to TipRanks.com, Meehan is a

Analysts Offer Insights on Healthcare Companies: Agilent (NYSE: A) and Bausch Health Companies Inc (NYSE: BHC)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Agilent (A – Research Report) and Bausch Health Companies Inc (BHC – Research Report) with bullish sentiments. Agilent (A) In a report

Quest Diagnostics Inc (DGX) Receives a Buy from Barclays

Barclays analyst Jack Meehan maintained a Buy rating on Quest Diagnostics Inc (DGX – Research Report) today and set a price target of $114. The company’s shares opened today at $86.04. Meehan wrote: “We were surprised there was another leg

Barclays Believes IQVIA Holdings Inc (NYSE: IQV) Won’t Stop Here

Barclays analyst Jack Meehan maintained a Buy rating on IQVIA Holdings Inc (IQV – Research Report) yesterday and set a price target of $155. The company’s shares closed yesterday at $141.13, close to its 52-week high of $143.42. According to

Barclays Maintains Their Buy Rating on Quidel Corp (QDEL)

Barclays analyst Jack Meehan maintained a Buy rating on Quidel Corp (QDEL – Research Report) yesterday and set a price target of $74. The company’s shares closed yesterday at $64.30. According to TipRanks.com, Meehan is a 4-star analyst with an

Charles River Labs (CRL) Receives a Hold from Barclays

Barclays analyst Jack Meehan maintained a Hold rating on Charles River Labs (CRL – Research Report) yesterday and set a price target of $135. The company’s shares closed yesterday at $139.12, close to its 52-week high of $139.91. According to